|
Volumn 15, Issue 4, 1997, Pages 343-352
|
Long-term response to crisnatol mesylate in patients with glioma
a a a a a a a |
Author keywords
Crisnatol mesylate; Efficacy; Malignant glioma; Safety
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CRISNATOL MESYLATE;
ADULT;
AGED;
ARTICLE;
CANCER SURVIVAL;
CLINICAL ARTICLE;
CLINICAL TRIAL;
FEMALE;
GASTROINTESTINAL SYMPTOM;
GLIOBLASTOMA;
GLIOMA;
GRANULOCYTOPENIA;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
LIVER TOXICITY;
LONG TERM CARE;
MALE;
MULTICENTER STUDY;
NEUROTOXICITY;
OLIGODENDROGLIOMA;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROGNOSIS;
RELAPSE;
REMISSION;
STOMATITIS;
TREATMENT OUTCOME;
ADULT;
ANTINEOPLASTIC AGENTS;
ASTROCYTOMA;
BRAIN NEOPLASMS;
CHRYSENES;
COMBINED MODALITY THERAPY;
FEMALE;
GLIOBLASTOMA;
GLIOMA;
HUMANS;
KARNOFSKY PERFORMANCE STATUS;
MAGNETIC RESONANCE IMAGING;
MALE;
MIDDLE AGED;
PROPYLENE GLYCOLS;
SURVIVAL ANALYSIS;
TOMOGRAPHY, X-RAY COMPUTED;
|
EID: 0031424068
PISSN: 01676997
EISSN: None
Source Type: Journal
DOI: 10.1023/A:1005968700694 Document Type: Article |
Times cited : (7)
|
References (15)
|